37 results
PRE 14A
LRMR
Larimar Therapeutics Inc
12 Apr 24
Preliminary proxy
6:06am
. Shankar served as Vice President and Global Head, Biologics Development Sciences at Janssen Research & Development, Inc. (“Janssen R&D … ”), a pharmaceutical company of Johnson & Johnson, Inc. (“Johnson & Johnson”) from April 2018 to April 2022, where he led a global, 175-person R&D department
8-K
EX-99.2
LRMR
Larimar Therapeutics Inc
10 Nov 22
Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results
7:01am
, Discovery & Non-clinical R&D Noreen Scherer VP, Clinical Operations Michael Celano Chief Financial Officer Keith E. Lynch, Jr. VP, Manufacturing
8-K
EX-99.1
statnao1bk lk9nwkrq
20 Oct 22
October 2022 Larimar Therapeutics Corporate Presentation
8:11am
8-K
EX-99.2
qfda3q ocs85
14 Sep 22
Other Events
7:05am
8-K
EX-99.2
sxssf l3tpmfebe9
11 Aug 22
Larimar plans to submit a complete response to CTI-1601’s clinical hold in the third quarter of 2022
4:13pm
8-K
EX-99.2
ticw 0jel1sti3xrdwz
12 May 22
Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results
7:12am
8-K
EX-99.2
zazek6gd tybp7zql4
25 Mar 22
Larimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial Results
7:11am
8-K
EX-99.1
8nu33odd
28 Feb 22
Results of Operations and Financial Condition
8:16am
8-K
EX-99.2
btfxa4d2wifu1lb6 hm
12 Nov 21
Larimar Therapeutics Reports Third Quarter 2021 Operating and Financial Results
7:21am
8-K
EX-99.2
gw890
12 Aug 21
Larimar Therapeutics Reports Second Quarter 2021 Operating and Financial Results
10:29am
8-K
EX-99.1
s2n35wb1
1 Jul 21
Other Events
6:11am
8-K
EX-99.1
3qbmly 2hhr
14 Jun 21
Other Events
5:21pm
8-K
EX-99.1
0w9balnf31 4s2hk0j6
18 May 21
Other Events
3:09pm
8-K
EX-99.1
rokoaws712cqq4qy0ec
8 Dec 20
Regulation FD Disclosure
7:40am
8-K
EX-99.2
qclegvygye
10 Nov 20
Larimar Therapeutics Reports Third Quarter 2020 Operating and Financial Results
4:23pm